Global Meropenem Market
Global Meropenem Market

Meropenem Comprehensive Study by Type (Injection, Freeze-dried powder), Application (Hospital use, Clinic, Others), Distribution Channel (Online, Offline) Players and Region - Global Market Outlook to 2024

Meropenem Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

Aug 2019 Edition 246 Pages 186 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Meropenem Market Overview:
Meropenem is a carbapenem antibiotic, which is active against gram-positive and gram-negative bacteria. Meropenem penetrate bacterial cells by interfering with the synthesis of vital cell wall components, which leads to cell death. Meropenem injection does not work for cold, flu or other viral infections. Taking antibiotics when they are not needed increases the risk of getting an infection which afterwards resists antibiotic treatment. Meropenem is an important option for the empirical treatment of serious bacterial infections in hospitalized patients. Some of the key players profiled in the study are Pfizer (United States), Shenzhen Haibin Pharmaceutical (China), Novartis (Switzerland), Mylan (United States), Takeda (Japan), Hisun-Pfizer Pharmaceuticals (China), Sumitomo Pharmaceuticals (Japan), Sumitomo Dainippon Pharma Co. Ltd. (Japan), Astra Zeneca Pharma (India), Crucell Switzerland AG (Switzerland) and Abbott (United States).

On the basis of geography, the market of Meropenem has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Distribution Channel, the sub-segment i.e. Online will boost the Meropenem market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing awareness towards healthy lifestyle
  • Rising prevalence of skin infection across the globe

Market Trend
  • Growing use in empirical treatment
  • Effective in the treatment of bacterial meningitis

Restraints
  • Inappropriate use can affects adversely

Opportunities
  • Increasing healthcare infrastructure in developing countries

Challenges
  • Easy availability of substitutes


March 20, 2019: Pfizer secures exclusive option to acquire gene therapy company Vivet Therapeutics and On 7th Jan 2019 Takeda has acquired Shire


The companies are exploring the market by adopting mergers & acquisitions, expansions and investments as their preferred strategies. Key players are exploring new geographies through expansions and acquisitions across the globe to avail competitive advantage through combined collaborations.

Target Audience:
Manufacturers of pharmaceutical drugs, Suppliers of pharmaceutical drugs, Wholesalers, distributers and retailers of pharmaceutical drugs, Healthcare industry, Research Firms and Governmental bodies

Major Objectives Focused through this Study
• To define, describe, and forecast the Global Meropenem market on the basis of product [Injection and Freeze-dried powder] , application [Hospital use, Clinic and Others], key regions and end user
• To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
• To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
• Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
• To provide market size for various segments of the Meropenem market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
• To strategically profile the key players and analyzing their market shares and core competencies in the Meropenem industry
• To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are Spectrum Chemical Manufacturing Corp (United States), Shijiazhuang Pharma (China), GE Healthcare (United States) and Haikou Pharmaceutical Factory (China).
** Confirmation on availability of data would be informed prior purchase

While framing the research framework, major and emerging players operating in the Meropenem market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as Hoovers, Bloomberg BusinessWeek, and Dow Jones (Factiva), along with primary respondents. The complete methodology includes the study of the annual and financial reports of the key market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) related to the market.
Report Objectives / Segmentation Covered
By Type
  • Injection
  • Freeze-dried powder
By Application
  • Hospital use
  • Clinic
  • Others
By Distribution Channel
  • Online
  • Offline

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing awareness towards healthy lifestyle
      • 3.2.2. Rising prevalence of skin infection across the globe
    • 3.3. Market Challenges
      • 3.3.1. Easy availability of substitutes
    • 3.4. Market Trends
      • 3.4.1. Growing use in empirical treatment
      • 3.4.2. Effective in the treatment of bacterial meningitis
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Meropenem, by Type, Application, Distribution Channel and Region (value, volume and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Meropenem (Value)
      • 5.2.1. Global Meropenem by: Type (Value)
        • 5.2.1.1. Injection
        • 5.2.1.2. Freeze-dried powder
      • 5.2.2. Global Meropenem by: Application (Value)
        • 5.2.2.1. Hospital use
        • 5.2.2.2. Clinic
        • 5.2.2.3. Others
      • 5.2.3. Global Meropenem by: Distribution Channel (Value)
        • 5.2.3.1. Online
        • 5.2.3.2. Offline
      • 5.2.4. Global Meropenem Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Meropenem (Volume)
      • 5.3.1. Global Meropenem by: Type (Volume)
        • 5.3.1.1. Injection
        • 5.3.1.2. Freeze-dried powder
      • 5.3.2. Global Meropenem by: Application (Volume)
        • 5.3.2.1. Hospital use
        • 5.3.2.2. Clinic
        • 5.3.2.3. Others
      • 5.3.3. Global Meropenem by: Distribution Channel (Volume)
        • 5.3.3.1. Online
        • 5.3.3.2. Offline
      • 5.3.4. Global Meropenem Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Meropenem (Price)
      • 5.4.1. Global Meropenem by: Type (Price)
  • 6. Meropenem: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Shenzhen Haibin Pharmaceutical (China)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novartis (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Mylan (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Takeda (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Hisun-Pfizer Pharmaceuticals (China)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sumitomo Pharmaceuticals (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sumitomo Dainippon Pharma Co. Ltd. (Japan)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Astra Zeneca Pharma (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Crucell Switzerland AG (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Abbott (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Meropenem Sale, by Type, Application, Distribution Channel and Region (value, volume and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Meropenem (Value)
      • 7.2.1. Global Meropenem by: Type (Value)
        • 7.2.1.1. Injection
        • 7.2.1.2. Freeze-dried powder
      • 7.2.2. Global Meropenem by: Application (Value)
        • 7.2.2.1. Hospital use
        • 7.2.2.2. Clinic
        • 7.2.2.3. Others
      • 7.2.3. Global Meropenem by: Distribution Channel (Value)
        • 7.2.3.1. Online
        • 7.2.3.2. Offline
      • 7.2.4. Global Meropenem Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Meropenem (Volume)
      • 7.3.1. Global Meropenem by: Type (Volume)
        • 7.3.1.1. Injection
        • 7.3.1.2. Freeze-dried powder
      • 7.3.2. Global Meropenem by: Application (Volume)
        • 7.3.2.1. Hospital use
        • 7.3.2.2. Clinic
        • 7.3.2.3. Others
      • 7.3.3. Global Meropenem by: Distribution Channel (Volume)
        • 7.3.3.1. Online
        • 7.3.3.2. Offline
      • 7.3.4. Global Meropenem Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Meropenem (Price)
      • 7.4.1. Global Meropenem by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Meropenem: by Type(USD Million)
  • Table 2. Meropenem Injection , by Region USD Million (2013-2018)
  • Table 3. Meropenem Freeze-dried powder , by Region USD Million (2013-2018)
  • Table 4. Meropenem: by Application(USD Million)
  • Table 5. Meropenem Hospital use , by Region USD Million (2013-2018)
  • Table 6. Meropenem Clinic , by Region USD Million (2013-2018)
  • Table 7. Meropenem Others , by Region USD Million (2013-2018)
  • Table 8. Meropenem: by Distribution Channel(USD Million)
  • Table 9. Meropenem Online , by Region USD Million (2013-2018)
  • Table 10. Meropenem Offline , by Region USD Million (2013-2018)
  • Table 11. South America Meropenem, by Country USD Million (2013-2018)
  • Table 12. South America Meropenem, by Type USD Million (2013-2018)
  • Table 13. South America Meropenem, by Application USD Million (2013-2018)
  • Table 14. South America Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 15. Brazil Meropenem, by Type USD Million (2013-2018)
  • Table 16. Brazil Meropenem, by Application USD Million (2013-2018)
  • Table 17. Brazil Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 18. Argentina Meropenem, by Type USD Million (2013-2018)
  • Table 19. Argentina Meropenem, by Application USD Million (2013-2018)
  • Table 20. Argentina Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 21. Rest of South America Meropenem, by Type USD Million (2013-2018)
  • Table 22. Rest of South America Meropenem, by Application USD Million (2013-2018)
  • Table 23. Rest of South America Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 24. Asia Pacific Meropenem, by Country USD Million (2013-2018)
  • Table 25. Asia Pacific Meropenem, by Type USD Million (2013-2018)
  • Table 26. Asia Pacific Meropenem, by Application USD Million (2013-2018)
  • Table 27. Asia Pacific Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 28. China Meropenem, by Type USD Million (2013-2018)
  • Table 29. China Meropenem, by Application USD Million (2013-2018)
  • Table 30. China Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 31. Japan Meropenem, by Type USD Million (2013-2018)
  • Table 32. Japan Meropenem, by Application USD Million (2013-2018)
  • Table 33. Japan Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 34. India Meropenem, by Type USD Million (2013-2018)
  • Table 35. India Meropenem, by Application USD Million (2013-2018)
  • Table 36. India Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 37. South Korea Meropenem, by Type USD Million (2013-2018)
  • Table 38. South Korea Meropenem, by Application USD Million (2013-2018)
  • Table 39. South Korea Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 40. Taiwan Meropenem, by Type USD Million (2013-2018)
  • Table 41. Taiwan Meropenem, by Application USD Million (2013-2018)
  • Table 42. Taiwan Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 43. Australia Meropenem, by Type USD Million (2013-2018)
  • Table 44. Australia Meropenem, by Application USD Million (2013-2018)
  • Table 45. Australia Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 46. Rest of Asia-Pacific Meropenem, by Type USD Million (2013-2018)
  • Table 47. Rest of Asia-Pacific Meropenem, by Application USD Million (2013-2018)
  • Table 48. Rest of Asia-Pacific Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 49. Europe Meropenem, by Country USD Million (2013-2018)
  • Table 50. Europe Meropenem, by Type USD Million (2013-2018)
  • Table 51. Europe Meropenem, by Application USD Million (2013-2018)
  • Table 52. Europe Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 53. Germany Meropenem, by Type USD Million (2013-2018)
  • Table 54. Germany Meropenem, by Application USD Million (2013-2018)
  • Table 55. Germany Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 56. France Meropenem, by Type USD Million (2013-2018)
  • Table 57. France Meropenem, by Application USD Million (2013-2018)
  • Table 58. France Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 59. Italy Meropenem, by Type USD Million (2013-2018)
  • Table 60. Italy Meropenem, by Application USD Million (2013-2018)
  • Table 61. Italy Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 62. United Kingdom Meropenem, by Type USD Million (2013-2018)
  • Table 63. United Kingdom Meropenem, by Application USD Million (2013-2018)
  • Table 64. United Kingdom Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 65. Netherlands Meropenem, by Type USD Million (2013-2018)
  • Table 66. Netherlands Meropenem, by Application USD Million (2013-2018)
  • Table 67. Netherlands Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 68. Rest of Europe Meropenem, by Type USD Million (2013-2018)
  • Table 69. Rest of Europe Meropenem, by Application USD Million (2013-2018)
  • Table 70. Rest of Europe Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 71. MEA Meropenem, by Country USD Million (2013-2018)
  • Table 72. MEA Meropenem, by Type USD Million (2013-2018)
  • Table 73. MEA Meropenem, by Application USD Million (2013-2018)
  • Table 74. MEA Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 75. Middle East Meropenem, by Type USD Million (2013-2018)
  • Table 76. Middle East Meropenem, by Application USD Million (2013-2018)
  • Table 77. Middle East Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 78. Africa Meropenem, by Type USD Million (2013-2018)
  • Table 79. Africa Meropenem, by Application USD Million (2013-2018)
  • Table 80. Africa Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 81. North America Meropenem, by Country USD Million (2013-2018)
  • Table 82. North America Meropenem, by Type USD Million (2013-2018)
  • Table 83. North America Meropenem, by Application USD Million (2013-2018)
  • Table 84. North America Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 85. United States Meropenem, by Type USD Million (2013-2018)
  • Table 86. United States Meropenem, by Application USD Million (2013-2018)
  • Table 87. United States Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 88. Canada Meropenem, by Type USD Million (2013-2018)
  • Table 89. Canada Meropenem, by Application USD Million (2013-2018)
  • Table 90. Canada Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 91. Mexico Meropenem, by Type USD Million (2013-2018)
  • Table 92. Mexico Meropenem, by Application USD Million (2013-2018)
  • Table 93. Mexico Meropenem, by Distribution Channel USD Million (2013-2018)
  • Table 94. Meropenem Sales: by Type(K Units)
  • Table 95. Meropenem Sales Injection , by Region K Units (2013-2018)
  • Table 96. Meropenem Sales Freeze-dried powder , by Region K Units (2013-2018)
  • Table 97. Meropenem Sales: by Application(K Units)
  • Table 98. Meropenem Sales Hospital use , by Region K Units (2013-2018)
  • Table 99. Meropenem Sales Clinic , by Region K Units (2013-2018)
  • Table 100. Meropenem Sales Others , by Region K Units (2013-2018)
  • Table 101. Meropenem Sales: by Distribution Channel(K Units)
  • Table 102. Meropenem Sales Online , by Region K Units (2013-2018)
  • Table 103. Meropenem Sales Offline , by Region K Units (2013-2018)
  • Table 104. South America Meropenem Sales, by Country K Units (2013-2018)
  • Table 105. South America Meropenem Sales, by Type K Units (2013-2018)
  • Table 106. South America Meropenem Sales, by Application K Units (2013-2018)
  • Table 107. South America Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 108. Brazil Meropenem Sales, by Type K Units (2013-2018)
  • Table 109. Brazil Meropenem Sales, by Application K Units (2013-2018)
  • Table 110. Brazil Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 111. Argentina Meropenem Sales, by Type K Units (2013-2018)
  • Table 112. Argentina Meropenem Sales, by Application K Units (2013-2018)
  • Table 113. Argentina Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 114. Rest of South America Meropenem Sales, by Type K Units (2013-2018)
  • Table 115. Rest of South America Meropenem Sales, by Application K Units (2013-2018)
  • Table 116. Rest of South America Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 117. Asia Pacific Meropenem Sales, by Country K Units (2013-2018)
  • Table 118. Asia Pacific Meropenem Sales, by Type K Units (2013-2018)
  • Table 119. Asia Pacific Meropenem Sales, by Application K Units (2013-2018)
  • Table 120. Asia Pacific Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 121. China Meropenem Sales, by Type K Units (2013-2018)
  • Table 122. China Meropenem Sales, by Application K Units (2013-2018)
  • Table 123. China Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 124. Japan Meropenem Sales, by Type K Units (2013-2018)
  • Table 125. Japan Meropenem Sales, by Application K Units (2013-2018)
  • Table 126. Japan Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 127. India Meropenem Sales, by Type K Units (2013-2018)
  • Table 128. India Meropenem Sales, by Application K Units (2013-2018)
  • Table 129. India Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 130. South Korea Meropenem Sales, by Type K Units (2013-2018)
  • Table 131. South Korea Meropenem Sales, by Application K Units (2013-2018)
  • Table 132. South Korea Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 133. Taiwan Meropenem Sales, by Type K Units (2013-2018)
  • Table 134. Taiwan Meropenem Sales, by Application K Units (2013-2018)
  • Table 135. Taiwan Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 136. Australia Meropenem Sales, by Type K Units (2013-2018)
  • Table 137. Australia Meropenem Sales, by Application K Units (2013-2018)
  • Table 138. Australia Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 139. Rest of Asia-Pacific Meropenem Sales, by Type K Units (2013-2018)
  • Table 140. Rest of Asia-Pacific Meropenem Sales, by Application K Units (2013-2018)
  • Table 141. Rest of Asia-Pacific Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 142. Europe Meropenem Sales, by Country K Units (2013-2018)
  • Table 143. Europe Meropenem Sales, by Type K Units (2013-2018)
  • Table 144. Europe Meropenem Sales, by Application K Units (2013-2018)
  • Table 145. Europe Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 146. Germany Meropenem Sales, by Type K Units (2013-2018)
  • Table 147. Germany Meropenem Sales, by Application K Units (2013-2018)
  • Table 148. Germany Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 149. France Meropenem Sales, by Type K Units (2013-2018)
  • Table 150. France Meropenem Sales, by Application K Units (2013-2018)
  • Table 151. France Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 152. Italy Meropenem Sales, by Type K Units (2013-2018)
  • Table 153. Italy Meropenem Sales, by Application K Units (2013-2018)
  • Table 154. Italy Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 155. United Kingdom Meropenem Sales, by Type K Units (2013-2018)
  • Table 156. United Kingdom Meropenem Sales, by Application K Units (2013-2018)
  • Table 157. United Kingdom Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 158. Netherlands Meropenem Sales, by Type K Units (2013-2018)
  • Table 159. Netherlands Meropenem Sales, by Application K Units (2013-2018)
  • Table 160. Netherlands Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 161. Rest of Europe Meropenem Sales, by Type K Units (2013-2018)
  • Table 162. Rest of Europe Meropenem Sales, by Application K Units (2013-2018)
  • Table 163. Rest of Europe Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 164. MEA Meropenem Sales, by Country K Units (2013-2018)
  • Table 165. MEA Meropenem Sales, by Type K Units (2013-2018)
  • Table 166. MEA Meropenem Sales, by Application K Units (2013-2018)
  • Table 167. MEA Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 168. Middle East Meropenem Sales, by Type K Units (2013-2018)
  • Table 169. Middle East Meropenem Sales, by Application K Units (2013-2018)
  • Table 170. Middle East Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 171. Africa Meropenem Sales, by Type K Units (2013-2018)
  • Table 172. Africa Meropenem Sales, by Application K Units (2013-2018)
  • Table 173. Africa Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 174. North America Meropenem Sales, by Country K Units (2013-2018)
  • Table 175. North America Meropenem Sales, by Type K Units (2013-2018)
  • Table 176. North America Meropenem Sales, by Application K Units (2013-2018)
  • Table 177. North America Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 178. United States Meropenem Sales, by Type K Units (2013-2018)
  • Table 179. United States Meropenem Sales, by Application K Units (2013-2018)
  • Table 180. United States Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 181. Canada Meropenem Sales, by Type K Units (2013-2018)
  • Table 182. Canada Meropenem Sales, by Application K Units (2013-2018)
  • Table 183. Canada Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 184. Mexico Meropenem Sales, by Type K Units (2013-2018)
  • Table 185. Mexico Meropenem Sales, by Application K Units (2013-2018)
  • Table 186. Mexico Meropenem Sales, by Distribution Channel K Units (2013-2018)
  • Table 187. Meropenem: by Type(USD/Units)
  • Table 188. Company Basic Information, Sales Area and Its Competitors
  • Table 189. Company Basic Information, Sales Area and Its Competitors
  • Table 190. Company Basic Information, Sales Area and Its Competitors
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Meropenem: by Type(USD Million)
  • Table 200. Meropenem Injection , by Region USD Million (2019-2024)
  • Table 201. Meropenem Freeze-dried powder , by Region USD Million (2019-2024)
  • Table 202. Meropenem: by Application(USD Million)
  • Table 203. Meropenem Hospital use , by Region USD Million (2019-2024)
  • Table 204. Meropenem Clinic , by Region USD Million (2019-2024)
  • Table 205. Meropenem Others , by Region USD Million (2019-2024)
  • Table 206. Meropenem: by Distribution Channel(USD Million)
  • Table 207. Meropenem Online , by Region USD Million (2019-2024)
  • Table 208. Meropenem Offline , by Region USD Million (2019-2024)
  • Table 209. South America Meropenem, by Country USD Million (2019-2024)
  • Table 210. South America Meropenem, by Type USD Million (2019-2024)
  • Table 211. South America Meropenem, by Application USD Million (2019-2024)
  • Table 212. South America Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 213. Brazil Meropenem, by Type USD Million (2019-2024)
  • Table 214. Brazil Meropenem, by Application USD Million (2019-2024)
  • Table 215. Brazil Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 216. Argentina Meropenem, by Type USD Million (2019-2024)
  • Table 217. Argentina Meropenem, by Application USD Million (2019-2024)
  • Table 218. Argentina Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 219. Rest of South America Meropenem, by Type USD Million (2019-2024)
  • Table 220. Rest of South America Meropenem, by Application USD Million (2019-2024)
  • Table 221. Rest of South America Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 222. Asia Pacific Meropenem, by Country USD Million (2019-2024)
  • Table 223. Asia Pacific Meropenem, by Type USD Million (2019-2024)
  • Table 224. Asia Pacific Meropenem, by Application USD Million (2019-2024)
  • Table 225. Asia Pacific Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 226. China Meropenem, by Type USD Million (2019-2024)
  • Table 227. China Meropenem, by Application USD Million (2019-2024)
  • Table 228. China Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 229. Japan Meropenem, by Type USD Million (2019-2024)
  • Table 230. Japan Meropenem, by Application USD Million (2019-2024)
  • Table 231. Japan Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 232. India Meropenem, by Type USD Million (2019-2024)
  • Table 233. India Meropenem, by Application USD Million (2019-2024)
  • Table 234. India Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 235. South Korea Meropenem, by Type USD Million (2019-2024)
  • Table 236. South Korea Meropenem, by Application USD Million (2019-2024)
  • Table 237. South Korea Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 238. Taiwan Meropenem, by Type USD Million (2019-2024)
  • Table 239. Taiwan Meropenem, by Application USD Million (2019-2024)
  • Table 240. Taiwan Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 241. Australia Meropenem, by Type USD Million (2019-2024)
  • Table 242. Australia Meropenem, by Application USD Million (2019-2024)
  • Table 243. Australia Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 244. Rest of Asia-Pacific Meropenem, by Type USD Million (2019-2024)
  • Table 245. Rest of Asia-Pacific Meropenem, by Application USD Million (2019-2024)
  • Table 246. Rest of Asia-Pacific Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 247. Europe Meropenem, by Country USD Million (2019-2024)
  • Table 248. Europe Meropenem, by Type USD Million (2019-2024)
  • Table 249. Europe Meropenem, by Application USD Million (2019-2024)
  • Table 250. Europe Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 251. Germany Meropenem, by Type USD Million (2019-2024)
  • Table 252. Germany Meropenem, by Application USD Million (2019-2024)
  • Table 253. Germany Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 254. France Meropenem, by Type USD Million (2019-2024)
  • Table 255. France Meropenem, by Application USD Million (2019-2024)
  • Table 256. France Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 257. Italy Meropenem, by Type USD Million (2019-2024)
  • Table 258. Italy Meropenem, by Application USD Million (2019-2024)
  • Table 259. Italy Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 260. United Kingdom Meropenem, by Type USD Million (2019-2024)
  • Table 261. United Kingdom Meropenem, by Application USD Million (2019-2024)
  • Table 262. United Kingdom Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 263. Netherlands Meropenem, by Type USD Million (2019-2024)
  • Table 264. Netherlands Meropenem, by Application USD Million (2019-2024)
  • Table 265. Netherlands Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 266. Rest of Europe Meropenem, by Type USD Million (2019-2024)
  • Table 267. Rest of Europe Meropenem, by Application USD Million (2019-2024)
  • Table 268. Rest of Europe Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 269. MEA Meropenem, by Country USD Million (2019-2024)
  • Table 270. MEA Meropenem, by Type USD Million (2019-2024)
  • Table 271. MEA Meropenem, by Application USD Million (2019-2024)
  • Table 272. MEA Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 273. Middle East Meropenem, by Type USD Million (2019-2024)
  • Table 274. Middle East Meropenem, by Application USD Million (2019-2024)
  • Table 275. Middle East Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 276. Africa Meropenem, by Type USD Million (2019-2024)
  • Table 277. Africa Meropenem, by Application USD Million (2019-2024)
  • Table 278. Africa Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 279. North America Meropenem, by Country USD Million (2019-2024)
  • Table 280. North America Meropenem, by Type USD Million (2019-2024)
  • Table 281. North America Meropenem, by Application USD Million (2019-2024)
  • Table 282. North America Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 283. United States Meropenem, by Type USD Million (2019-2024)
  • Table 284. United States Meropenem, by Application USD Million (2019-2024)
  • Table 285. United States Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 286. Canada Meropenem, by Type USD Million (2019-2024)
  • Table 287. Canada Meropenem, by Application USD Million (2019-2024)
  • Table 288. Canada Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 289. Mexico Meropenem, by Type USD Million (2019-2024)
  • Table 290. Mexico Meropenem, by Application USD Million (2019-2024)
  • Table 291. Mexico Meropenem, by Distribution Channel USD Million (2019-2024)
  • Table 292. Meropenem Sales: by Type(K Units)
  • Table 293. Meropenem Sales Injection , by Region K Units (2019-2024)
  • Table 294. Meropenem Sales Freeze-dried powder , by Region K Units (2019-2024)
  • Table 295. Meropenem Sales: by Application(K Units)
  • Table 296. Meropenem Sales Hospital use , by Region K Units (2019-2024)
  • Table 297. Meropenem Sales Clinic , by Region K Units (2019-2024)
  • Table 298. Meropenem Sales Others , by Region K Units (2019-2024)
  • Table 299. Meropenem Sales: by Distribution Channel(K Units)
  • Table 300. Meropenem Sales Online , by Region K Units (2019-2024)
  • Table 301. Meropenem Sales Offline , by Region K Units (2019-2024)
  • Table 302. South America Meropenem Sales, by Country K Units (2019-2024)
  • Table 303. South America Meropenem Sales, by Type K Units (2019-2024)
  • Table 304. South America Meropenem Sales, by Application K Units (2019-2024)
  • Table 305. South America Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 306. Brazil Meropenem Sales, by Type K Units (2019-2024)
  • Table 307. Brazil Meropenem Sales, by Application K Units (2019-2024)
  • Table 308. Brazil Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 309. Argentina Meropenem Sales, by Type K Units (2019-2024)
  • Table 310. Argentina Meropenem Sales, by Application K Units (2019-2024)
  • Table 311. Argentina Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 312. Rest of South America Meropenem Sales, by Type K Units (2019-2024)
  • Table 313. Rest of South America Meropenem Sales, by Application K Units (2019-2024)
  • Table 314. Rest of South America Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 315. Asia Pacific Meropenem Sales, by Country K Units (2019-2024)
  • Table 316. Asia Pacific Meropenem Sales, by Type K Units (2019-2024)
  • Table 317. Asia Pacific Meropenem Sales, by Application K Units (2019-2024)
  • Table 318. Asia Pacific Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 319. China Meropenem Sales, by Type K Units (2019-2024)
  • Table 320. China Meropenem Sales, by Application K Units (2019-2024)
  • Table 321. China Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 322. Japan Meropenem Sales, by Type K Units (2019-2024)
  • Table 323. Japan Meropenem Sales, by Application K Units (2019-2024)
  • Table 324. Japan Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 325. India Meropenem Sales, by Type K Units (2019-2024)
  • Table 326. India Meropenem Sales, by Application K Units (2019-2024)
  • Table 327. India Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 328. South Korea Meropenem Sales, by Type K Units (2019-2024)
  • Table 329. South Korea Meropenem Sales, by Application K Units (2019-2024)
  • Table 330. South Korea Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 331. Taiwan Meropenem Sales, by Type K Units (2019-2024)
  • Table 332. Taiwan Meropenem Sales, by Application K Units (2019-2024)
  • Table 333. Taiwan Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 334. Australia Meropenem Sales, by Type K Units (2019-2024)
  • Table 335. Australia Meropenem Sales, by Application K Units (2019-2024)
  • Table 336. Australia Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 337. Rest of Asia-Pacific Meropenem Sales, by Type K Units (2019-2024)
  • Table 338. Rest of Asia-Pacific Meropenem Sales, by Application K Units (2019-2024)
  • Table 339. Rest of Asia-Pacific Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 340. Europe Meropenem Sales, by Country K Units (2019-2024)
  • Table 341. Europe Meropenem Sales, by Type K Units (2019-2024)
  • Table 342. Europe Meropenem Sales, by Application K Units (2019-2024)
  • Table 343. Europe Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 344. Germany Meropenem Sales, by Type K Units (2019-2024)
  • Table 345. Germany Meropenem Sales, by Application K Units (2019-2024)
  • Table 346. Germany Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 347. France Meropenem Sales, by Type K Units (2019-2024)
  • Table 348. France Meropenem Sales, by Application K Units (2019-2024)
  • Table 349. France Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 350. Italy Meropenem Sales, by Type K Units (2019-2024)
  • Table 351. Italy Meropenem Sales, by Application K Units (2019-2024)
  • Table 352. Italy Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 353. United Kingdom Meropenem Sales, by Type K Units (2019-2024)
  • Table 354. United Kingdom Meropenem Sales, by Application K Units (2019-2024)
  • Table 355. United Kingdom Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 356. Netherlands Meropenem Sales, by Type K Units (2019-2024)
  • Table 357. Netherlands Meropenem Sales, by Application K Units (2019-2024)
  • Table 358. Netherlands Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 359. Rest of Europe Meropenem Sales, by Type K Units (2019-2024)
  • Table 360. Rest of Europe Meropenem Sales, by Application K Units (2019-2024)
  • Table 361. Rest of Europe Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 362. MEA Meropenem Sales, by Country K Units (2019-2024)
  • Table 363. MEA Meropenem Sales, by Type K Units (2019-2024)
  • Table 364. MEA Meropenem Sales, by Application K Units (2019-2024)
  • Table 365. MEA Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 366. Middle East Meropenem Sales, by Type K Units (2019-2024)
  • Table 367. Middle East Meropenem Sales, by Application K Units (2019-2024)
  • Table 368. Middle East Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 369. Africa Meropenem Sales, by Type K Units (2019-2024)
  • Table 370. Africa Meropenem Sales, by Application K Units (2019-2024)
  • Table 371. Africa Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 372. North America Meropenem Sales, by Country K Units (2019-2024)
  • Table 373. North America Meropenem Sales, by Type K Units (2019-2024)
  • Table 374. North America Meropenem Sales, by Application K Units (2019-2024)
  • Table 375. North America Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 376. United States Meropenem Sales, by Type K Units (2019-2024)
  • Table 377. United States Meropenem Sales, by Application K Units (2019-2024)
  • Table 378. United States Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 379. Canada Meropenem Sales, by Type K Units (2019-2024)
  • Table 380. Canada Meropenem Sales, by Application K Units (2019-2024)
  • Table 381. Canada Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 382. Mexico Meropenem Sales, by Type K Units (2019-2024)
  • Table 383. Mexico Meropenem Sales, by Application K Units (2019-2024)
  • Table 384. Mexico Meropenem Sales, by Distribution Channel K Units (2019-2024)
  • Table 385. Meropenem: by Type(USD/Units)
  • Table 386. Research Programs/Design for This Report
  • Table 387. Key Data Information from Secondary Sources
  • Table 388. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Meropenem: by Type USD Million (2013-2018)
  • Figure 5. Global Meropenem: by Application USD Million (2013-2018)
  • Figure 6. Global Meropenem: by Distribution Channel USD Million (2013-2018)
  • Figure 7. South America Meropenem Share (%), by Country
  • Figure 8. Asia Pacific Meropenem Share (%), by Country
  • Figure 9. Europe Meropenem Share (%), by Country
  • Figure 10. MEA Meropenem Share (%), by Country
  • Figure 11. North America Meropenem Share (%), by Country
  • Figure 12. Global Meropenem: by Type K Units (2013-2018)
  • Figure 13. Global Meropenem: by Application K Units (2013-2018)
  • Figure 14. Global Meropenem: by Distribution Channel K Units (2013-2018)
  • Figure 15. South America Meropenem Share (%), by Country
  • Figure 16. Asia Pacific Meropenem Share (%), by Country
  • Figure 17. Europe Meropenem Share (%), by Country
  • Figure 18. MEA Meropenem Share (%), by Country
  • Figure 19. North America Meropenem Share (%), by Country
  • Figure 20. Global Meropenem: by Type USD/Units (2013-2018)
  • Figure 21. Global Meropenem share by Players 2018 (%)
  • Figure 22. Global Meropenem share by Players (Top 3) 2018(%)
  • Figure 23. Global Meropenem share by Players (Top 5) 2018(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 26. Pfizer (United States) Revenue: by Geography 2018
  • Figure 27. Shenzhen Haibin Pharmaceutical (China) Revenue, Net Income and Gross profit
  • Figure 28. Shenzhen Haibin Pharmaceutical (China) Revenue: by Geography 2018
  • Figure 29. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. Novartis (Switzerland) Revenue: by Geography 2018
  • Figure 31. Mylan (United States) Revenue, Net Income and Gross profit
  • Figure 32. Mylan (United States) Revenue: by Geography 2018
  • Figure 33. Takeda (Japan) Revenue, Net Income and Gross profit
  • Figure 34. Takeda (Japan) Revenue: by Geography 2018
  • Figure 35. Hisun-Pfizer Pharmaceuticals (China) Revenue, Net Income and Gross profit
  • Figure 36. Hisun-Pfizer Pharmaceuticals (China) Revenue: by Geography 2018
  • Figure 37. Sumitomo Pharmaceuticals (Japan) Revenue, Net Income and Gross profit
  • Figure 38. Sumitomo Pharmaceuticals (Japan) Revenue: by Geography 2018
  • Figure 39. Sumitomo Dainippon Pharma Co. Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 40. Sumitomo Dainippon Pharma Co. Ltd. (Japan) Revenue: by Geography 2018
  • Figure 41. Astra Zeneca Pharma (India) Revenue, Net Income and Gross profit
  • Figure 42. Astra Zeneca Pharma (India) Revenue: by Geography 2018
  • Figure 43. Crucell Switzerland AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 44. Crucell Switzerland AG (Switzerland) Revenue: by Geography 2018
  • Figure 45. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 46. Abbott (United States) Revenue: by Geography 2018
  • Figure 47. Global Meropenem: by Type USD Million (2019-2024)
  • Figure 48. Global Meropenem: by Application USD Million (2019-2024)
  • Figure 49. Global Meropenem: by Distribution Channel USD Million (2019-2024)
  • Figure 50. South America Meropenem Share (%), by Country
  • Figure 51. Asia Pacific Meropenem Share (%), by Country
  • Figure 52. Europe Meropenem Share (%), by Country
  • Figure 53. MEA Meropenem Share (%), by Country
  • Figure 54. North America Meropenem Share (%), by Country
  • Figure 55. Global Meropenem: by Type K Units (2019-2024)
  • Figure 56. Global Meropenem: by Application K Units (2019-2024)
  • Figure 57. Global Meropenem: by Distribution Channel K Units (2019-2024)
  • Figure 58. South America Meropenem Share (%), by Country
  • Figure 59. Asia Pacific Meropenem Share (%), by Country
  • Figure 60. Europe Meropenem Share (%), by Country
  • Figure 61. MEA Meropenem Share (%), by Country
  • Figure 62. North America Meropenem Share (%), by Country
  • Figure 63. Global Meropenem: by Type USD/Units (2019-2024)
Some of the key companies/manufacturers profiled in the report
  • Pfizer (United States)
  • Shenzhen Haibin Pharmaceutical (China)
  • Novartis (Switzerland)
  • Mylan (United States)
  • Takeda (Japan)
  • Hisun-Pfizer Pharmaceuticals (China)
  • Sumitomo Pharmaceuticals (Japan)
  • Sumitomo Dainippon Pharma Co. Ltd. (Japan)
  • Astra Zeneca Pharma (India)
  • Crucell Switzerland AG (Switzerland)
  • Abbott (United States)
Additional players considered in the study are as follows:
Spectrum Chemical Manufacturing Corp (United States) , Shijiazhuang Pharma (China) , GE Healthcare (United States) , Haikou Pharmaceutical Factory (China)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation